Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment (clinicaltrials.gov) - Dec 8, 2022 - P1 | N=40 | Not yet recruiting | Sponsor: Plus Therapeutics | Initiation date: Aug 2022 ➔ Dec 2022
Trial initiation date • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor
|